What science can do

Annual Report and Form 20-F
Information 2020

01

Our Purpose

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

We are committed to operating in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet.


02

Chairman & CEO




03

Strategic overview

We are a global pharmaceutical business with a science-led and patient-focused value proposition:

  • Focus on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism (CVRM); and Respiratory & Immunology (R&I)
  • Diversified portfolio of specialty and primary care medicines
  • Global strength, balanced presence across regions
  • Commitment to people and society



36

Pipeline progression events
(2019: 22)


53

Regulatory events
(2019: 63)



$26,617m

Total Revenue
(2019: $24,384m)



89%

Employee belief that AstraZeneca is a great place to work
(2019: 86%)


93%

Sustainability scorecard performance
(2019: 86%)



04

COVID-19 response

AstraZeneca’s response to the COVID-19 pandemic was consistent with our Values of following the science, putting patients first and doing the right thing.

Our priorities were driven by the needs of patients, caregivers and communities. To respond effectively, we partnered with governments, international organisations, healthcare practitioners, industry and non-profit organisations.


Our priorities



05

Financial Highlights

In 2020, Total Revenue, comprising Product Sales and Collaboration Revenue, increased by 9% (10% at CER) to $26,617 million. Product Sales grew by 10% (11% at CER) to $25,890 million. Collaboration Revenue fell by 11% (11% at CER) to $727 million.

Total Revenue from New Medicines increased by 33% (33% at CER) to $13,950 million, representing 52% of Total Revenue (2019: 43%).


Revenue and Cash


Total Revenue*                                   
Up 9% at actual rate of exchange to $26,617 million (up 10% at CER), comprising Product Sales of $25,890 million (up 10%; 11% at CER) and Collaboration Revenue of $727 million (down 11%; 11% at CER)

$26.6bn


Net cash flow from operating activities
Up 62% at actual rate of exchange to $4,799 million                                    



                                                  

$4.8bn

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

*Total Revenue consists of Product Sales and Collaboration Revenue.

 

Operating profit


Reported operating profit
Up 77% at actual rate of exchange to $5,162 million (up 81% at CER)


$5.2bn


Core operating profit
Up 14% at actual rate of exchange to $7,340 million (up 17% at CER)          


$7.3bn

EPS


Reported EPS
Up 137% at actual rate of exchange to $2.44 (up 142% at CER)


$2.44


Core EPS
Up 15% at actual rate of exchange to $4.02 (up 18% at CER)


$4.02

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.



06

Sustainability Highlights

In 2020, we continued toward our ambition of leading in sustainability. We presented at the United Nations General Assembly on health system resiliency, in support of broadening access to healthcare; progressed our Ambition Zero Carbon commitment, now sourcing 99.9% of our imported electricity globally from renewable sources; and deepened our commitment to inclusion and diversity by committing to ensure racial equity in our workplace and access to our medicines.


Access to healthcare



Access to healthcare


Our ambitions to 2025:

Work towards a future where all people have access to sustainable healthcare solutions for life-changing treatment and disease prevention


Our global development impact:


Progress in 2020:

25.0m

People reached through our access to healthcare programmes
(2019: 20.5m)

Environmental protection



Environmental protection


Our ambitions to 2025:

Demonstrate global leadership to proactively manage our environmental impact across all our activities and products.


Our global development impact:


Progress in 2020:

248 kt CO2e

Scope 1 and 2 greenhouse gas (GHG) footprint
(2019: 385 kt CO2e)

Ethics and transparency



Ethics and transparency


Our ambitions to 2025:

Create positive societal impact and promote ethical behaviour in all markets across our value chain.


Our global development impact:


Progress in 2020:

49.1 cases per 1,000 employees

in Commercial Business Units in non-compliance with our Code of Ethics
(2019: 63.3)


For more information on our targets and performance, and contribution to the UN Sustainable Development Goals, see our 2020 Sustainability Report available on our website, www.astrazeneca.com/sustainability.